| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
Rasusterol (DUR-928; 0-25 μM; 8 h; HepG2 cells) trimethylamine inhibits cholesterol biosynthesis by reducing HMG-CoA reductase mRNA levels and reduces free [14C] cholesterol levels in a dose-dependent manner [1]. Rasusterol (0-25 μM; 6 h; HepG2 cells) trimethylamine inhibits HMG-CoA reductase expression by inhibiting the activation and expression of SREBP1 in hepatocytes [1]. Rasusterol (0-50 μM; 48 h) trimethylamine promotes macrophage proliferation and reduces apoptosis [2]. Rasusterol (0-25 μM; 48 h; macrophages) trimethylamine inhibits the activation of hepatic oxosterol receptor LXRα [2].
|
|---|---|
| ln Vivo |
Rasusterol (DUR-928; 25 mg/kg; intraperitoneal injection; twice every 14 hours; C57BL/6J mouse non-alcoholic fatty liver (NAFLD) model) Trimethylamine can reduce blood lipid levels in mice fed a high-fat diet [3]. Rasusterol (25 mg/kg; intraperitoneal injection; twice every 14 hours; C57BL/6J mouse non-alcoholic fatty liver (NAFLD) model) Trimethylamine can inhibit gene expression and inhibit ABCA1 expression. Rasusterol can increase the level of nuclear SREBP-1 protein and cytoplasmic FAS and ACC1 protein in liver tissue [3]. Rasusterol (25 mg/kg; intraperitoneal injection; once every 3 days for 6 weeks; C57BL/6J mouse non-alcoholic fatty liver (NAFLD) model) Trimethylamine can protect the liver from damage by inhibiting liver inflammation [3].
|
| Animal Protocol |
Animal/Disease Models:Female C57BL/6J mice with non-alcoholic fatty liver disease (NAFLD) [3]
Doses: 25 mg/kg< Route of Administration:Intraperitoneal injection; twice every 14 hours Experimental Results:Plasma triglycerides (TG), total cholesterol (CHOL), and high-density lipoprotein cholesterol (HDL-C) decreased by 40%, 15%, and 20%, respectively. The mRNA levels of SREBP-1c, ACC1, and FAS decreased by 46%, 57%, and 49%, respectively. ABCA1 expression was inhibited. The levels of nuclear SREBP-1, cytoplasmic ACC1, and FAS proteins decreased by 74%, 58%, and 47%, respectively. Animal/Disease Models:Female C57BL/6J mice, non-alcoholic fatty liver disease (NAFLD) model [3] Doses: 25 mg/kg Route of Administration: Intraperitoneal injection; once every 3 days for 6 weeks Experimental Results: Decreased plasma cholesterol levels. Decreased serum alkaline phosphatase, ALT and AST levels. |
| References |
|
| Molecular Formula |
C27H46O5S.0.45C3H9N
|
|---|---|
| Molecular Weight |
509.32
|
| Related CAS # |
Larsucosterol; Larsucosterol sodium; Larsucosterol ammonium; 2655654-16-1
|
| Appearance |
Off-white to yellow solid
|
| SMILES |
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCCC(C)(O)C)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)OS(=O)(O)=O)=CC3)C.CN(C)C.[0.45]
|
| Synonyms |
DUR-928 trimethylamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~65.44 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.91 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9634 mL | 9.8170 mL | 19.6340 mL | |
| 5 mM | 0.3927 mL | 1.9634 mL | 3.9268 mL | |
| 10 mM | 0.1963 mL | 0.9817 mL | 1.9634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
